Imaging for Ischemic Cardiomyopathy Prognosis
This study is looking at new ways to understand heart health in people with coronary artery disease, especially those who have had or will have a coronary artery bypass graft (CABG). Researchers are using three special imaging tests: Hyperpolarized 13C Pyruvate Magnetic Resonance Imaging (HP-13C MRI), [¹⁸F]Fluorodeoxyglucose Positron Emission Tomography (FDG-PET), and SPECT Myocardial Perfusion Imaging (SPECT MPI). These tests help doctors see how well your heart muscle is working and if it's healthy. The study aims to combine these imaging methods to get a more complete picture of heart metabolism and viability. They are looking for 12 to 15 participants, including healthy individuals and those with advanced ischemic cardiomyopathy. The main goal is to assess heart metabolism and viability using these imaging techniques before CABG surgery.
- Study design
- This is an observational study that will include 12 to 15 participants, divided into two groups: healthy individuals and patients with ischemic cardiomyopathy. It is a single-center study, meaning it takes place at one location.
- What's involved
- Participants will undergo baseline imaging at enrollment, which includes HP-13C MRI, FDG-PET, and SPECT MPI. The SPECT MPI involves both a rest and stress study.
- Compensation
- Not stated in the trial record.
- Follow-up
- The primary endpoints are measured at baseline imaging at enrollment (pre-CABG), so there is no specified follow-up period after this initial assessment.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Hyperpolarized 13C Pyruvate-MRI and FDG-PET in a Single Exam for the Prognosis of Ischemic Cardiomyopathy
At a glance
Conditions
Where it's being run
1 sites across 1 statesStudy leadership
- Gaurav Sharma, PhD, MBA · PRINCIPAL_INVESTIGATOR · University of Texas Southwestern Medical Center
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Assessment of Myocardial Metabolism and Viability via HP-13C MRI, FDG-PET, and SPECT MPIBaseline imaging at enrollment (pre-CABG)
This outcome evaluates the ability of hyperpolarized 13C pyruvate MRI (HP-13C MRI) to assess myocardial metabolism, alongside myocardial viability assessment using FDG-PET and SPECT MPI, in patients with ischemic cardiomyopathy compared with healthy subjects. Quantitative assessment with HP-13C MRI will focus on the metabolic conversion of pyruvate to intermediates like bicarbonate and lactate as a marker of oxidative versus anaerobic metabolism. These results will be compared with regional FDG uptake measured by FDG-PET and perfusion findings from SPECT MPI. The performance of these metabolic biomarkers will be evaluated and compared with established viability imaging techniques to determine their relative accuracy in characterizing ischemic cardiomyopathy.